Urologas Antanas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 14,404 | 12,404 | 14,318 | 11,970 | 21,151 | 8,320 | 10,360 | 3,041 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -2,466 | -2,642 | 2,916 | 412 | 11,174 | -1,137 | 277 | -478 |
| Equity | -10,523 | -13,165 | -10,248 | -9,836 | 1,338 | 201 | 478 | 0 |
| Liabilities | 11,228 | 14,073 | 10,538 | 10,785 | 104 | 249 | 302 | 0 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 705 | 908 | 290 | 949 | 1,442 | 450 | 780 | 0 |
| Total assets | 705 | 908 | 290 | 949 | 1,442 | 450 | 780 | 0 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 621 | 678 | 226 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -8.9% | -13.9% | +15.4% | -16.4% | +76.7% | -60.7% | +24.5% | -70.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -349.8% | -291.0% | 1005.5% | 43.4% | 774.9% | -252.7% | 35.5% | - |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 835.1% | -565.7% | 57.9% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -17.1% | -21.3% | 20.4% | 3.4% | 52.8% | -13.7% | 2.7% | -15.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.1 | 1.2 | 0.6 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 14,404 | 12,404 | 14,318 | 11,970 | 21,151 | 8,320 | 10,360 | 3,041 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Urologas Antanas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-07-16 | 2025-07-20 | 6.76 |
| 2025-06-17 | 2025-06-25 | 5.28 |
| 2025-05-16 | 2025-05-20 | 55.22 |
| 2025-05-04 | 2025-05-15 | 0.03 |
| 2025-04-24 | 2025-04-29 | 0.03 |
| 2025-03-18 | 2025-03-30 | 5.85 |
| 2025-02-18 | 2025-02-23 | 5.82 |
| 2024-05-16 | 2024-06-09 | 0.03 |
| 2024-02-19 | 2024-03-11 | 4.46 |
Urologas Antanas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-03 | 2025-05-03 | 56.48 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Urologas Antanas, UAB (code 300156760) is a Private Limited Liability Company engaged in medical specialists activities. The company operated on a small scale in 2025, when revenue amounted to €3.0K and net profit was -€478, indicating a return to loss after a profit in 2024. Revenue increased from €8.3K in 2023 to €10.4K in 2024, when net profit reached €277, but then declined sharply in 2025. Based on the available figures, revenue fell by 70.7% year on year in 2025 and by 63.5% compared with two years earlier, showing a clear weakening in turnover after the 2024 peak. Profitability also moved from a loss in 2023 to a small profit in 2024 and then back to a loss in 2025. The latest balance sheet information available is for 2024, when total assets were €780, equity stood at €478 and liabilities at €302. Overall, the company remains very small, with results that have been volatile over the last three years.